No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://www.nature.com/articles/s41416-021-01676-4.pdf
Reference38 articles.
1. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–205. https://doi.org/10.1016/S0140-6736(16)32616-2.
2. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32:3744–52. https://doi.org/10.1200/JCO.2014.55.5730.
3. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl J Med. 2015;372:724–34. https://doi.org/10.1056/NEJMoa1413513.
4. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2019; https://doi.org/10.1056/nejmoa1914609.
5. Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2020;38:3138–49. https://doi.org/10.1200/JCO.20.00147.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Optimal therapeutic strategies for hepatic metachronous oligometastatic nasopharyngeal carcinoma: Insights from a retrospective study;International Journal of Cancer;2024-08-26
2. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives;Nature Reviews Clinical Oncology;2024-01-08
3. Long-term Survival Among Patients With De Novo Human Epidermal Growth Receptor 2–Positive Metastatic Breast Cancer in Manitoba;American Journal of Clinical Oncology;2023-12-04
4. Assessment of Selenium and Mercury Levels in Breast Tissue of Malignant and Healthy Female Patients in Pakistan: Implications for Breast Cancer Screening and Treatment;2023-11-07
5. Nanostructured bioactive glasses: A bird's eye view on cancer therapy;WIREs Nanomedicine and Nanobiotechnology;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3